Eli Lilly's tirzepatide is off the FDA's shortage list: What it means for patients
Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...
FiercePharma7h
Lilly joins OAC campaign against obesity stigma, partnering on gallery of bias-free images for use in media coverage
Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...
Why Eli Lilly Stock Is Soaring—And How It Plans To Stay On Top
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.
Seeking Alpha3d
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (NYSE:LLY) has partnered with the British ... tirzepatide, branded as Zepbound. Writing for the U.K.’s The Telegraph newspaper, Secretary of State for Health & Social Care Wes ...
FiercePharma4d
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
3 Reasons Eli Lilly Stock Isn't Going to Run out of Steam Anytime Soon
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
This is Huge News For Eli Lilly Investors
Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.
ConsumerAffairs1d
Compounding pharmacies can keep making Mounjaro and Zepbound copies
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...